Results 301 to 310 of about 356,203 (328)

Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia

Nature, 1994
Achondroplasia, the most common cause of chondrodysplasia in man (1 in 15,000 live births), is a condition of unknown origin characterized by short-limbed dwarfism and macrocephaly. More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals, suggesting that de novo mutations are of ...
F, Rousseau, J, Bonaventure, L, Legeai-Mallet, A, Pelet, J M, Rozet, P, Maroteaux, M, Le Merrer, A, Munnich   +7 more
openaire   +2 more sources

Fibroblast Growth Factor Receptor-3 as a Marker for Precartilaginous Stem Cells

Clinical Orthopaedics and Related Research, 1999
The epiphyseal organ contains two kinds of cartilage, articular and growth plate. Both enlarge during the growth phase of life. However, mitosis is not apparent in these tissues. In the current study, a search to trace the reservoirs of stem cells needed for the growth of these cartilages is done. A disorder in which the stem cells responsible for bone
D, Robinson, A, Hasharoni, N, Cohen, A, Yayon, R M, Moskowitz, Z, Nevo   +5 more
openaire   +2 more sources

Molecular cloning and developmental expression of rat fibroblast growth factor receptor 3

Histochemistry and Cell Biology, 2001
Fibroblast growth factors (FGFs) are involved in the control of a variety of biological functions including regulation and differentiation of various cell types. Furthermore, they play important roles in the processes of regeneration, angiogenesis, and chemotaxis.
P, Claus, C, Grothe
openaire   +2 more sources

Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia

Acta Paediatrica, 2000
Hypochondroplasia is characterized by a disproportionate short stature with rhizomelic shortening of the limbs. Amino acid substitutions Asn540Lys, Asn540Thr and Ile538Val in the fibroblast growth factor receptor 3 (FGFR3) are considered to cause hypochondroplasia.
G, Grigelioniené, O, Eklöf, E, Laurencikas, B, Ollars, N T, Hertel, J P, Dumanski, L, Hagenäs   +6 more
openaire   +2 more sources

Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.

Cancer research, 2001
Autosomal dominant disorders of skeletal and cranial development have been linked to fibroblast growth factor receptor (FGFR) 2 and FGFR3. Here we report two identical mutations in FGFR2 that cause craniosynostosis syndromes, Crouzon, Apert, and Pfeiffer in gastric carcinoma.
J H, Jang, K H, Shin, J G, Park
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Cancer treatment and survivorship statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Kimberly D Miller, Leticia M Nogueira, Angela B Mariotto   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Regulation of chondrocyte growth and differentiation by fibroblast growth factor receptor 3.

Novartis Foundation symposium, 2001
Both gain-of-function and loss-of-function mutations in fibroblast growth factor receptor 3 (Fgfr3) have revealed unique roles for this receptor during skeletal development. Loss-of-function alleles of Fgfr3 lead to an increase in the size of the hypertrophic zone, delayed closure of the growth plate and the subsequent overgrowth of long bones. Gain-of-
openaire   +1 more source